The combination of this therapy with immune checkpoint inhibition (hu14.18-IL2 + RT + anti-CTLA-4) further amplified anti-tumor responses and resulted in greater tumor regression and improved animal survival when compared to IC, RT or anti-CTLA-4 given alone, or dual combinations of: (1) RT + IC, (2) RT + anti-CTLA-4, or (3) IC + anti-CTLA-4 (9). The gene discussed is IL2; the disease is neoplasm.